Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer

Silvia Prislei; Enrica Martinelli; Gian Franco Zannoni; Marco Petrillo; Flavia Filippetti; Marisa Mariani; Simona Mozzetti; Giuseppina Raspaglio; Giovanni Scambia; Cristiano Ferlini

doi:10.18632/oncotarget.3943

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer

Silvia Prislei _, Enrica Martinelli, Gian Franco Zannoni, Marco Petrillo, Flavia Filippetti, Marisa Mariani, Simona Mozzetti, Giuseppina Raspaglio, Giovanni Scambia and Cristiano Ferlini

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:18966-18979. https://doi.org/10.18632/oncotarget.3943

Metrics: PDF 2470 views | HTML 2248 views | ?

Abstract

Silvia Prislei1, Enrica Martinelli1, Gian Franco Zannoni1,2, Marco Petrillo1, Flavia Filippetti1, Marisa Mariani3, Simona Mozzetti1, Giuseppina Raspaglio1, Giovanni Scambia1, Cristiano Ferlini1,3

1Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy

2Department of Pathology, Catholic University of the Sacred Heart, Rome, Italy

3Reproductive Tumor Biology Research, Biomedical Lab, Department of Obstetrics and Gynecology, Danbury Hospital, Danbury, CT, USA

Correspondence to:

Silvia Prislei, e-mail: [email protected]

Keywords: ZEB2, EMT, HuR, ovarian cancer

Received: December 09, 2014 Accepted: May 05, 2015 Published: May 15, 2015

ABSTRACT

ZEB2 is a key factor in epithelial-mesenchymal transition (EMT), a program controlling cell migration in embryonic development and adult tissue homeostasis. We demonstrated a role of ZEB2 in migration and anchorage-independent cell growth in ovarian cancer, as shown by ZEB2 silencing. We found that the RNA-binding protein HuR bound the 3′UTR of ZEB2 mRNA, acting as a positive regulator of ZEB2 protein expression. In Hey ovarian cell line, HuR silencing decreased ZEB2 and ZEB1 nuclear expression and impaired migration. In hypoglycemic conditions ZEB2 expression decreased, along with ZEB1, vimentin and cytoplasmic HuR, and a reduced cellular migration ability was observed. Analysis of ZEB2 and HuR expression in ovarian cancers revealed that nuclear ZEB2 is localized in tumor leading edge and co-localizes with cytoplasmic HuR. In a series of 143 ovarian cancer patients high expression of ZEB2 mRNA significantly correlated with a poor prognosis in term of both overall survival and progression- free survival. Moreover, at immunohistochemical evaluation, we found that prognostic significance of ZEB2 protein relies on its nuclear expression and co-localization with cytoplasmic HuR. In conclusion our findings indicated that nuclear ZEB2 may enhance progression of EMT transition and acquisition of an aggressive phenotype in ovarian cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3943

Publication Alerts

Research Papers:

Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer

Abstract